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Abstract
Categorization of primary cutaneous B- cell lymphomas (PCBCL) other than 
marginal zone (MZL) represents a diagnostic challenge with relevant prog-
nostic implications. The 2008 WHO lymphoma classification recognizes only 
primary cutaneous follicular center cell lymphoma (PCFCCL) and primary 
cutaneous diffuse large B- cell lymphoma, leg type (PCDLBCL- LT), whereas 
the previous 2005 WHO/EORTC classification also included an intermediate 
form, namely PCDLBCL, other. We conducted a retrospective, multicentric, 
consensus- based revision of the clinicopathologic characteristics of 161 cases 
of PCBCL other than MZL. Upon the histologic features that are listed in 
the WHO classification, 96 cases were classified as PCFCCL and 25 as 
PCDLBCL- LT; 40 further cases did not fit in the former subgroups in terms 
of cytology and/or architecture, thus were classified as PCDLBCL, not oth-
erwise specified (PCDLBCL- NOS). We assigned all the cases a histogenetic 
profile, based on the immunohistochemical detection of CD10, BCL6, and 
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Introduction
The issue of classification of primary cutaneous B- cell 
lymphomas (PCBCL) other than marginal zone lymphoma 
(MZL) has been matter of debate. The 2008 WHO 
Lymphoma Classification [1] recognizes two subtypes: 
primary cutaneous follicular center cell lymphoma 
(PCFCCL) and primary cutaneous diffuse large B- cell 
lymphoma, leg type (PCDLBCL- LT). PCFCCL is defined 
on the basis of cytological features (presence of centro-
cytes) irrespective of growth pattern, which may be variable 
from follicular to predominantly diffuse; in some case, 
mostly advanced tumors, the lymphoma infiltrate may 
contain a prevalence of large cells, a feature which seems 
not to affect prognosis. PCDLBCL- LT designs all cutane-
ous B- cell lymphomas with a diffuse pattern and composed 
of monotonous proliferation of centroblasts and immu-
noblasts, usually BCL2- positive, irrespective of site of 
presentation. This two- tiered distinction was validated by 
clinical studies [2, 3] and was partially supported by the 
identification of different molecular signatures and imbal-
ances [4] in PCFCCL and PCDLBCL- LT, the latter resem-
bling the activated B- cell type (ABC) of nodal DLBCL 
[5, 6].
In the previous WHO/EORTC classification (2005) [7, 
8], the heading of cutaneous diffuse large B- cell lympho-
mas comprised several variants, including PCDLBCL- LT, 
cases with peculiar morphology (T- cell/histiocyte rich, 
plasmablastic) as well as diffuse lymphomas of 
centroblastic- like cells, intermingled with a mixed inflam-
matory infiltrate and with variable expression of BCL2, 
which are named primary cutaneous diffuse large B- cell 
lymphoma, other (PCDLBCL- O). PCDLBCL- O basically 
represents a morphological variant lacking the typical 
features of PCDLBCL- LT neither conforming to the defi-
nition of PCFCCL, whereas on the clinical ground, its 
behavior seems at least to partially overlap the indolent 
course of PCFCCL. In fact, the present WHO lymphoma 
classification overcame the previous WHO/EORTC and 
included at least a part of PCDLBCL- O within the spec-
trum of PCFCCL.
In spite of the advances in the classification, the iden-
tification of this putative variant remains not trivial, since 
it might harbor significant prognostic and therapeutic 
implications. While the 5- year disease- specific survival in 
PCDLBCL- LT is 41%, PCFCCL carries an excellent prog-
nosis, with a 95% 5- year survival [1] even in cases fea-
turing a predominance of large cells, which may benefit 
from a conservative therapeutic approach. Since only few 
studies focused on such issue and indeed no conclusive 
data are available on large series [9, 10], question still 
remains whether such group of PCBCL with borderline 
features between PCFCCL and PCDLBCL- LT could define 
a further distinct category.
To clarify the existence of an additional clinicopathologic 
subset of PCLBCL, we retrospectively analyzed a large 
multicentric series of PCBCL other than MZL and tested 
the prognostic relevance of several factors, including cyto-
morphologic features, histogenetic profiles, and BCL2 status 
[11].
Methods
Selection of patients
This multicentric study retrospectively analyzed the clin-
icopathologic features of a series of 197 PCBCL other 
than MZL, diagnosed between 1993 and 2010 at 10 centers 
referring to the “Gruppo Italiano di studio dei Linfomi 
Cutanei (G.I.L.C.)” of the “Fondazione Italiana Linfomi 
(F.I.L.).” Approval for this study was obtained from the 
local institutional ethical committee. Data management 
was made according to the Helsinki Declaration of 1975, 
revised in 1983 and 2000.
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MUM1, and a “double hit score” upon positivity for BCL2 and MYC. 
PCDLBCL- NOS had a clinical presentation more similar to PCFCCL, whereas 
the histology was more consistent with the picture of a diffuse large B- cell 
lymphoma, as predominantly composed of centroblasts but with intermixed 
a reactive infiltrate of small lymphocytes. Its behavior was intermediate be-
tween the other two forms, particularly when considering only cases with a 
“non- germinal B- cell” profile, whereas “germinal center” cases resembled 
PCFCCL. Our data confirmed the aggressive behavior of PCDLBC- LT, which 
often coexpressed MYC and BCL2. The impact of single factors on 5- year 
survival was documented, particularly histogenetic profile in PCDLBCL and 
BCL2 translocation in PCFCCL. Our study confirms that a further group—
PCDLBCL- NOS—exists, which can be recognized through a careful combina-
tion of histopathologic criteria coupled with adequate clinical information.
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Inclusion criteria were as follows: (1) primary cutaneous 
disease, documented through comprehensive staging, and 
no extracutaneous spread for at least 6 months after diag-
nosis; (2) availability of representative formalin- fixed, 
paraffin- embedded (FFPE) lesional blocks; and (3) clinical 
follow- up. A particular focus was addressed to cases featur-
ing a predominance of large cells, encompassing the whole 
spectrum of PCDLBCL according to both WHO and WHO/
EORTC classifications. Thirty- six cases were excluded 
because of a history of systemic lymphoma or limited 
follow- up.
Histological review
Immunohistochemistry
For all cases, histochemical and immunohistochemical 
staining was reviewed by a panel of six expert pathologists 
(M. P., E. B., C. T., S. A., M. G., and M. S.). Automated 
immunostainings were performed on FFPE slides through 
streptavidin- biotin- peroxidase- conjugated (SABC) method 
after antigen retrieval procedures, when needed. Tested 
antibodies included CD20, CD79a, BCL2, CD10, BCL6, 
MUM1, MYC, HGAL, CD138, CD3, CD5, Mib1/Ki- 67, 
CD21, CD23, CD30, BCL1, and ALK/p80. BCL2, BCL6, 
and CD10 immunostainings were considered positive if 
>50% of the cells were stained. MUM1 positivity was 
assessed upon a cutoff value of 30%. MiB1/Ki67 expres-
sion was assigned to a low (<50%) or high proliferative 
(>50%) index. Histogenesis was defined according to Hans 
algorithm [12], and thus a “germinal center B- cell” (GC) 
or a “non- germinal center B- cell” (non- GC) profile was 
assigned. The so- called double hit score (DHS) was assigned 
to DLBCL based on a cutoff value of 75% for BCL2 posi-
tivity and of 40% for MYC positivity [13].
Diagnoses were primarily based on the 2008 WHO 
classification criteria [1]. When a disagreement occurred, 
final diagnosis was obtained by consensus. Lesional archi-
tecture was identified as nodular, nodular/diffuse, or dif-
fuse; the presence of residual dendritic meshwork was 
noted. Cytologic features were defined primarily on nuclear 
morphology either as small- to- large centrocytes (cleaved 
cells) or as centroblasts and immunoblasts (nucleolated, 
noncleaved cells).
Cases with a predominance of small- to- large centrocytes 
and a minority of centroblasts/immunoblasts were classified 
as PCFCCL, independently from growth pattern (Fig. S1). 
Proliferations showing a diffuse pattern and mostly consist-
ing of centroblasts/immunoblasts with only few small, cen-
trocytoid lymphocytes were named PCDLBCL- LT (Fig. 1).
Cases almost entirely composed of large cells (centro-
blasts), though with a mixed inflammatory background 
and/or a minority (<10%) of large centrocytoid cells, and 
with a predominantly diffuse pattern were observed 
(Fig. 2). These tumors lacked the typical features both 
of PCDLBCL- LT and PCFCCL, and thus they were named 
PCDLBCL, not otherwise specified (PCDLBCL- NOS).
Figure 1. The typical picture of PCDLBCL- LT is represented, as tumoral lesions arising on the lower limbs (A), composed of a proliferation of large, 
round cells with centroblastic and/or immunoblastic features (B; Giemsa stain, 400×) and frequent coexpression of BCL2 and MYC (C and D; SABC 
method, 400×). PCDLBCL- LT, primary cutaneous diffuse large B- cell lymphoma, leg type; BCL2, B- cell lymphoma; SABC, streptavidin- biotin- 
peroxidase- conjugated.
A B
C D
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Molecular biology
Interphasic fluorescence in situ hybridization (FISH) analy-
sis for BCL2 translocation was performed on routine 
paraffin sections (3–4 μm) using an IGH/BCL2 Dual Color, 
Dual Fusion Translocation Probe (Vysis Abbott, Des 
Plaines, IL, USA). This probe is a mixture of the IGH 
probe, labeled with SpectrumGreen and spanning ~1.5 Mb, 
thus containing sequences homologous to the entire IGH 
locus as well as sequences extending about 300 kb beyond 
the 3′- end of the IGH locus, and the BCL2 probe, labeled 
Figure 2. This case of PCDLBCL- NOS arose as a tumoral lesion on the neck (A); histologic picture is consistent with a nodular to diffuse proliferation 
(B, hematoxylin–eosin, 100×) of predominantly large, centroblastic cells (C, Giemsa stain 400×) with a mixed inflammatory infiltrate (D, hematoxylin–
eosin 400×). Picture (C) is representative of a PCDLBCL- NOS- non- GC cases, which resulted MUM1- positive (E, SABC method, 400×), whereas CD10 
stain (F, SABC method, 400×) corresponds to the PCDLBCL- NOS- GC cases shown in picture (D). BCL2 is usually negative (G, SABC method, 400×), 
whereas the small, intermixed lymphocytes usually display a T- cell, CD3+ phenotype (H, SABC method, 400×). PCDLBCL- NOS- non- GC, primary 
cutaneous diffuse large B- cell lymphoma, not otherwise specified non- germinal center B- cell; SABC, streptavidin- biotin- peroxidase- conjugated.
A
C
B
D
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with SpectrumOrange and covering gene, covering an 
approximate 750- kb region. The expected pattern in a 
normal nucleus hybridized is the two orange, two green; 
if harboring a t(14;18), the most common pattern is one 
orange signal, one green signal, and two orange/green 
(yellow) fusion signals, representing the two derivative 
chromosomes resulting from the reciprocal translocation. 
The evaluation was carried out using direct viewing on 
a standard fluorescence microscope, and the images were 
elaborated with Powergene Macprobe v.4.4 software 
(Applied Imaging, Newcastle-upon-Tyne, UK). In each 
case, more than 100 nuclei on paraffin- embedded sections 
were examined; if more than 15% of nuclei displayed the 
translocation, we considered the case as positive.
Epstein-Barr virus (EBV) status was tested by in situ 
hybridization (ISH) using a fluorescein isothiocyanate- 
labeled peptic nucleic acid (PNA) probe, complementary 
to the EBV- encoded RNAs (EBERs) (DakoCytomation, 
Glostrup, Denmark).
Statistical analysis
Data were described as mean and standard deviation if 
continuous variable and counts and percent if categorical 
variable and compared between diagnostic groups with 
the one- way analysis of variance and the Fisher exact test, 
respectively. Survival and event- free survival were described 
with Kaplan–Meier method. Predictors were identified with 
the log- rank test, and the Cox model was used to compute 
the corresponding hazard ratios and their 95% confidence 
intervals (HR, 95% CI). The analysis was performed on 
the entire case series and on predefined meaningful sub-
groups. The median follow- up (25th–75th percentiles) was 
computed according to the inverse Kaplan–Meier method.
Stata13 (StataCorp, College Station, TX) was used for 
computation. A two- sided P- value was considered statisti-
cally significant. For post hoc comparisons, the Bonferroni 
correction was applied.
Results
Histological classification
According to the panel approach, 96/161 cases (59%) were 
classified as PCFCCL, 40/161 (25%) as PCDLBCL- NOS, 
and 25/161 (16%) as PCDLBCL- LT.
Briefly, in PCFCCL (Fig. S1), the infiltrate mainly con-
sisted of small- to medium- sized centrocytes, with a vari-
able amount of centroblasts, whereas large cells (both 
centrocytes and centroblasts) were predominant in 20/96 
(21%) cases. A spindle cell morphology was observed in 
11 cases. Growth pattern was nodular in 33/96 (34%) 
cases, nodular and diffuse in 39/96 (41%), and purely 
diffuse in 24/96 (25%), whereas remnants of follicular 
dendritic meshwork were usually observed. A reactive 
lymphocytic and histiocytic background was always present, 
at times so abundant to obscure the lymphoma B cells.
In PCDLBCL- NOS (Fig. 2), the infiltrate showed a 
purely diffuse growth pattern in 25/40 (63%) cases, while 
limited gross nodular areas were observed in 15/25 (37%) 
cases; in 11/40 (27%) cases, a residual dendritic meshwork 
was noted, though very focal and with features of disrup-
tion. Tumor cells were chiefly centroblasts and were usually 
intermingled with a variable reactive cellular background, 
mostly composed of small reactive CD3+ lymphocytes.
PCDLBCL- LT (Fig. 1) was composed exclusively of large 
round nucleolated cells, with predominance of immuno-
blasts, growing in a diffuse pattern with common efface-
ment of adnexa, focal necrosis with sparse nuclear debris, 
and a very scanty, if present, inflammatory background 
nor stromal reaction; no dendritic meshwork was detected.
Although within a wide range, median proliferative 
index was generally low in PCFCCL (30%, range 10–90%) 
and high in PCDLBCL- LT (70%, range 50–90%), whereas 
an intermediate value was documented in PCDLBCL- NOS 
(50%, range 10–90%).
All PCFCCLs were positive for either CD10 or Bcl6 and 
negative for MUM1, whereas PCDLBCL subtypes were split 
in the two histogenetic groups. For PCDLBCL- NOS, 26/40 
(65%) cases were recorded as GC and 14/40 (35%) as 
non- GC; among PCDLBCL- LT, 5/25 (20%) cases fell into 
GC and 20/25 (80%) into non- GC subgroup. MYC posi-
tivity was documented in 10 of 21 (48%) tested cases of 
PCDLBCL- NOS and in 11/13 (85%) PCDLBCL- LT, whereas 
it turned out to be negative in PCFCCL. As to DHS, cases 
were stratified into a two- tiered system (0–1 vs. 2): within 
PCDLBCL- NOS, 16/24 cases scored DHS = 0–1 and 8/24 
DHS = 2; among PCDLBCL- LT, 18 cases 5/18 cases scored 
DHS = 0–1 and 13/18 DHS = 2. Comprehensive histo-
pathologic and phenotypic features are detailed in Table 1.
Molecular biology
FISH analysis for BCL2 translocation was performed in 
122/161 (76%) cases (Table 1) and detected in 15/75 
(20%) PCFCCL, in 3/27 (11%) PCDLBCL- NOS, and in 
1/20 (5%) PCDLBCL- LT. EBV was tested in 30 PCDLBCL 
and resulted uniformly negative (Fig. S2).
Clinical presentation, therapy, and follow- up
Clinical features, therapy, and follow- up are summarized 
according to the panel diagnosis and detailed in Table 2. 
Among the three groups, a slight male- to- female prevalence 
was noticed; for PCDLBCL- LT, a tendency toward an older 
age of onset was highlighted. The number of lesions (single 
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vs. multiple) was balanced among the subgroups, whereas 
PCFCCL and PCDLBCL- NOS showed a predilection for 
trunk and head and neck location, in contrast to 
PCDLBCL- LT which involved preferentially the lower limbs.
Overall survival
On the whole series, the median follow- up was 48 months 
(25th–75th, 21–98). Median overall survival (OS) was not 
reached for any subgroup. According to the panel diagnosis 
(Fig. 3, Table 3), OS was significantly different between 
the three subgroups (P < 0.001). Post hoc comparisons 
scored a significantly different OS for PCFCCL versus 
PCDLBCL- LT (HR = 0.03, P < 0.001) and for PCDLBCL- 
NOS versus PCDLBCL- LT (HR = 0.13, P = 0.001); however, 
the comparison of PCFCCL versus PCDLBCL- NOS did 
not reach statistical significance (HR = 0.21, P = 0.073). 
When splitting PCDLBCL- NOS in two histogenetic sub-
groups, post hoc comparisons showed a difference in OS 
for PCDLBCL- NOS- GC versus PCDLBCL- NOS- non- GC, 
although not significant (HR = 0.15, P = 0.102). The 
difference in OS of PCDLBCL- NOS- GC was significant 
versus PCDLBCL- LT (HR = 0.05, P = 0.003) but not 
versus PCFCCL (HR = 0.58, P = 0.695). For PCDLBCL- 
NOS- non- GC, the comparison did not reach statistical 
significance versus PCDLBCL- LT (HR = 0.30, P = 0.070) 
but versus PCFCCL (HR = 0.09, P = 0.008).
The combination of PCFCCL and PCDLBCL- NOS- GC 
into a “germinal center” group was tested: this approach 
identified for PCFCCL+PCDLBCL- NOS- GC a significantly 
different OS as compared to the “high- grade” subgroup, 
identified as PCDLBCL- NOS- non- GC+PCDLBCL- LT (HR 
Table 1. Histologic features.
Histopathologic features PCFCCL PCDLBCL- NOS PCDLBCL- LT P
Cytology Prevalence of small 
to large, cleaved 
cells (centrocytes)
Prevalence of round, 
nucleolated cells (centro-
blasts, rarely immunoblasts)
Almost exclusively round, 
nucleolated cells (centro-
blasts and immunoblasts)
—
Reactive T cells Present Present Very scanty —
Growth pattern (%) Nodular to diffuse Typically diffuse Diffuse NA
Nodular 33/96 (34) 0/40 (0) 0/25 (0)
Nodular/diffuse 39/96 (41) 15/40 (38) 0/25 (0)
Diffuse 24/96 (25) 25/40 (62) 25/25 (100)
Dendritic meshwork, present (%) 80/96 (83) 11/40 (27)1 1/25 (4)1 <0.001
Infiltrate extension (%) <0.001
Dermic 44/96 (46) 22/40 (55) 0/25 (0)
Dermic/hypodermic 52/96 (54) 18/40 (45) 25/25 (100)
Skin ulceration (%) 0/96 (0) 4/40 (10) 4/25 (16) NA
Adnexal effacement, present (%) 3/96 (3) 6/40 (15) 10/25 (40) NA
Necrosis 0/96 (0) 2/40 (5) 4/25 (16) NA
Nuclear debris 0/96 (0) 4/40 (10) 15/25 (60) NA
Starry sky appearance 0/96 (0) 0/40 (0) 11/25 (44) NA
BCL2, +/total (%) 29/96 (30) 16/40 (40) 19/25 (76) <0.001
CD10, +/total (%) 57/96 (59) 11/40 (27) 0/25 (0) <0.001
BCL6, +/total (%) 84/96 (87) 33/40 (82) 14/25 (56) 0.001
MUM1, +/total (%) 0/96 (0) 14/40 (40) 20/25 (80) 0.004
HGAL, +/total (%) 50/54 (93) 9/40 (22) 1/25 (4) <0.001
MYC, +/total (%) 0/40 (0) 10/21 (48) 11/13 (85) <0.001
Ki67 median % (range) 30 (10–90) 50 (10–90) 70 (50–90) —
Histogenetic profile, GC/total (%) 96/96 (100) 26/40 (65) 5/25 (20) <0.001
DHS (%) All: <0.001
0–1 NA 16/24 5/18 NOS vs. LT: 0.28
2 NA 8/24 13/18
BCL2 translocation +/total (%) 15/75 (20) 3/27 (11) 1/20 (5) 0.234
BCL2 status (p) (<0.001) (0.273) (1) —
FISH+/IHC+ (%) 11/23 (48) 3/17 (17) 1/17 (6)
FISH+/IHC− (%) 4/52 (8) 0/10 (0) 0/3 (0)
EBV, +/total (%) NA 0/15 (0) 0/20 (0) NA
PCFCCL, primary cutaneous follicular center cell lymphoma; PCDLBCL- NOS, primary cutaneous diffuse large B- cell lymphoma, not otherwise specified; 
PCDLBCL- LT, primary cutaneous diffuse large B- cell lymphoma, leg type; GC, germinal center (Hans algorithm); DHS, double- hit score; NA, not as-
sessed (group too small for statistical analysis); FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
1Only very focal and disrupted, if present.
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0.05, P < 0.001). Interestingly, statistic significance was 
retained also toward, respectively, PCDLBCL- NOS- non- GC 
(HR = 0.10, P = 0.005) and PCDLBCL- LT (HR = 0.03, 
P = 0.001).
Event- free survival
Event- free survival (EFS) (Fig. 3, Table 3) was significantly 
different between the three panel diagnosis (P < 0.001). 
Post hoc analysis showed a significantly different EFS only 
for PCFCCL versus PCDLBCL- LT (HR = 0.21, P < 0.001) 
and for PCDLBCL- NOS versus PCDLBCL- LT (HR = 0.24, 
P < 0.001).
As to histogenetic subsets, paired comparison resulted in 
a significantly different EFS only for PCDLBCL- NOS- GC 
versus PCDLBCL- LT (HR = 0.19, P < 0.001) and for 
PCDLBCL- NOS- non- GC versus PCDLBCL- LT (HR = 0.38, 
P = 0.024).
Finally, PCFCCL+PCDLBCL- NOS- GC group had a 
higher EFS when compared to the “high- grade” group 
(HR = 0.31, P < 0.001) and to PCDLBCL- LT (HR = 0.20, 
P < 0.001), while EFS versus PCDLBCL- NOS- non- GC 
was still lower but not significant (HR = 0.53, 
P = 0.098).
Survival according to single factors
Univariable analysis is detailed in Table 4; a further test-
ing was conducted on the group of PCDLBCL 
(PCDLBCL- NOS+PCDLBCL- LT).
Table 2. Clinical features.
Clinical presentation PCFCCL PCDLBCL- NOS PCDLBCL- LT (%) P
Male/female (ratio) 53/43 (1.23) 27/13 (2.08) 17/8 (2.12) 0.432
Mean age (range) 54 (27–86) 63 (26–90) 76 (54–92) <0.001
Number of lesions (%)
Single lesion 67/96 (70) 27/40 (68) 18/25 (72) 0.889
Multiple lesions 29/96 (30) 13/40 (32) 6/25 (24)
Diffuse 0/96 (0) 0/40 (0) 1/25 (4)
Site involved (%)
Head and neck 38/96 (40) 7/40 (17) 0/25 (0) <0.001
Trunk 47/96 (49) 20/40 (50) 3/25 (12) 0.002
Upper limbs 8/96 (8) 8/40 (20) 1/25 (4) NA
Lower limbs 7/96 (7) 9/40 (22) 21/25 (84) <0.001
Type of lesion (%)
Nodule/tumor 64/96 (67) 27/40 (67) 18/25 (72) 0.878
Plaque 17/96 (18) 10/40 (25) 5/25 (20) 0.625
Patch 4/96 (4) 1/40 (3) 2/25 (8) NA
Papule 5/96 (5) 0/40 (0) 0/25 (0) NA
Variable 6/96 (6) 2/40 (5) 0/25 (0) NA
Therapy and follow- up
First- line therapy
Surgical only 20/96 (21) 2/40 (5) 0/25 (0) 0.004
Radiotherapy 47/96 (49) 15/40 (37) 9/25 (36) <0.001
Chemotherapy (±radio) 26/96 (27) 22/40 (55) 15/25 (60) 0.006
Wait and see 3/96 (3) 1/40 (3) 1/25 (4) NA
Response to therapy (%)
CR 81/96 (84) 32/40 (80) 13/25 (52) 0.002
PR 15/96 (16) 8/40 (20) 12/25 (48)
Relapse, /CR (%) 35/81 (43) 13/32 (41) 11/13 (85) 0.015
Extracutaneous relapse, /CR (%) 5/81 (6) 2/32 (6) 1/25 (4)
Median time to relapse, months (range) 24 (6–156) 26 (5–159) 11 (5–28) 0.156
Follow- up
ADF 76/96 (79) 25/40 (62) 4/25 (16) <0.001
AWD 15/96 (16) 10/40 (25) 8/25 (32) 0.140
DOD 2/96 (2) 4/40 (10) 11/25 (44) NA
DUC 3/96 (3) 1/40 (3) 2/25 (8) NA
Median follow- up, months (range) 47 (12–237) 53 (8–210) 19 (6–126) 0.007
PCFCCL, primary cutaneous follicular center cell lymphoma; PCDLBCL- NOS, primary cutaneous diffuse large B- cell lymphoma, not otherwise specified; 
PCDLBCL- LT, primary cutaneous diffuse large B- cell lymphoma, leg type; CR, complete response; PR, partial response; ADF, alive disease- free; AWD, 
alive with disease; DOD, died of disease; DUC, died of unrelated cause; NA, not assessed (group too small for statistical analysis).
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As to immunophenotypic features, on the complete series, 
a GC histogenetic profile distinguishes a whole group both 
with a better OS (HR = 0.07, P < 0.001) and EFS 
(HR = 0.32, P < 0.001); this observation was true also 
excluding PCDLBCL- LT cases from the analysis. BCL2 
positivity negatively impacted OS but not EFS on the whole 
series. According to the panel diagnosis, there was a trend 
toward ad increase in OS, though above the threshold of 
significance while an inverse tendency, though still not 
significant, was observed for EFS. OS was significantly 
impacted when considering only cases with a large cell 
histology (HR = 3.43, P = 0.043). DHS proved to impact 
OS (P < 0.001) and EFS (P = 0.011) on the whole series 
and to be helpful in identifying a subset of cases with a 
Figure 3. OS curves: analysis is performed comparing the three morphologic diagnosis, according to (A), the four groups obtained when splitting 
PCDLBCL- NOS according to histogenesis (B) and the three categories identified upon aggregation of PCFCCL and PCDLBCL- NOS- GC in a “germinal 
center” group (C); in the same way, EFS curves are reported (D–F). OS, overall survival; PCDLBCL- NOS- GC, primary cutaneous diffuse large B- cell 
lymphoma, not otherwise specified germinal center B- cell; PCFCCL, primary cutaneous follicular center cell lymphoma; EFS, event- free survival.
A
B
C
D
E
F
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lower survival in the large cell subgroup (HR = 3.43, 
P = 0.05).
Although based on few events, the presence of BCL2 
translocation proved to impact significantly OS in PCFCCL, 
whereas for EFS, it was significant only for PCDLBCL- LT.
Age at diagnosis >70 years correlated with a significantly 
lower OS (HR = 9.51, P = 0.003). Male sex resulted to be 
a factor of risk, although statistically significant only for EFS.
Lesional pattern (single vs. multiple lesions) did not 
show any significant impact. Localization on the lower 
limbs correlated with worse OS and EFS on the whole 
series, whereas according to the panel diagnosis, it was 
significant only for PCFCCL, however based on a single 
event. A significance was observed also in the large cell 
subgroup, with a lower OS and HR = 3.97 (P = 0.013) 
for leg site, whereas the highest OS was related to locali-
zation on the trunk.
Discussion
The controversies in PCBCL classification primarily reflect 
the rarity and clinical heterogeneity of the disease. From 
Table 3. OS and EFS according to the diagnosis and paired comparisons.
2- year OS % 5- year OS % P Paired comparisons HR P
Analysis of OS by panel diagnosis
PCFCCL 100 98.25 <0.001 PCFCCL vs. PCDLBCL- LT 0.03 (0.01–0.12) <0.001
PCDLBCL- NOS 93.98 93.98 PCDLBCL- NOS vs. PCDLBCL- LT 0.13 (0.04–0.41) 0.001
PCDLBCL- LT 58.96 52.41 PCFCCL vs. PCDLBCL- NOS 0.21 (0.04–1.16) 0.073
Analysis of OS by panel diagnosis + histogenesis
PCFCCL 100 95.96 <0.001 PCFCCL vs. PCDLBCL- LT 0.03 (0.01–0.12) <0.001
PCDLBCL- NOS- GC 95.45 95.45 PCFCCL vs. PCDLBCL- NOS- GC 0.58 (0.05–6.42) 0.695
PCDLBCL- NOS- non- GC 91.67 91.67 PCFCCL vs. PCDLBCL- NOS- non- GC 0.09 (0.01–0.53) 0.008
PCFLBCL- LT 58.96 52.41 PCDLBCL- NOS- GC vs. PCDLBCL- LT 0.05 (0.01–0.36) 0.003
PCDLBCL- NOS- non- GC vs. 
PCDLBCL- LT
0.30 (0.08–1.11) 0.070
PCDLBCL- NOS- GC vs. 
PCDLBCL- NOS- non- GC
0.15 (0.02–1.45) 0.102
Analysis of OS by combined groups
PCFCCL+PCDLBCL- 
NOS- GC
98.95 95.90 <0.001 PCFCCL+PCDLBCL- NOS- GC vs. 
PCDLBCL- LT
0.03 (0.01–0.11) <0.001
PCDLBCL- NOS- non- GC 91.96 91.96 PCDLBCL- NOS- non- GC vs. 
PCFLBCL- LT
0.30 (0.08–1.11) 0.070
PCDLBCL- LT 58.96 52.41 PCFCCL+PCDLBCL- NOS- GC vs. 
PCDLBCL- NOS- non- GC
0.10 (0.02–0.51) 0.005
Analysis of EFS by panel diagnosis
PCFCCL 75.29 51.67 <0.001 PCFCCL vs. PCDLBCL- LT 0.21 (0.12–0.37) <0.001
PCDLBCL- NOS 65.69 40.30 PCDLBCL- NOS vs. PCDLBCL- LT 0.24 (0.13–0.47) <0.001
PCDLBCL- LT 22.69 11.34 PCFCCL vs. PCDLBCL- NOS 0.86 (0.50–1.47) 0.582
Analysis of EFS by panel diagnosis + histogenesis
PCFCCL 75.29 51.67 <0.001 PCFCCL vs. PCDLBCL- LT 0.21 (0.12–0.37) <0.001
PCDLBCL- NOS- GC 70.69 48.95 PCFCCL vs. PCDLBCL- NOS- GC 1.08 (0.56–2.07) 0.817
PCDLBCL- NOS- non- GC 53.95 21.58 PCFCCL vs. PCDLBCL- NOS- non- GC 0.54 (0.25–1.16) 0.113
PCFLBCL- LT 22.69 11.34 PCDLBCL- NOS- GC vs. PCDLBCL- LT 0.19 (0.09–0.41) <0.001
PCDLBCL- NOS- non- GC vs. 
PCDLBCL- LT
0.38 (0.17–0.88) 0.024
PCDLBCL- NOS- GC vs. 
PCDLBCL- NOS- non- GC
0.50 (0.20–1.23) 0.135
Analysis of EFS by combined groups
PCFCCL+PCDLBCL- 
NOS- GC
74.27 51.13 <0.001 PCFCCL+PCDLBCL- NOS- GC vs. 
PCDLBCL- LT
0.20 (0.12–0.35) <0.001
PCDLBCL- NOS- non- GC 53.95 21.58 PCDLBCL- NOS- non- GC vs. 
PCFLBCL- LT
0.38 (0.17–0.88) 0.024
PCDLBCL- LT 22.69 11.34 PCFCCL+PCDLBCL- NOS- GC vs. 
PCDLBCL- NOS- non- GC
0.53 (0.25–1.12) 0.098
OS, overall survival; EFS, event-free survival; HR, hazard ratio; PCFCCL, primary cutaneous follicular center cell lymphoma; PCDLBCL- NOS, primary 
cutaneous diffuse large B- cell lymphoma, not otherwise specified; PCDLBCL- LT, primary cutaneous diffuse large B- cell lymphoma, leg type; PCDLBCL- 
NOS- GC, PCDLBCL- NOS germinal center B- cell; PCDLBCL- NOS- non- GC, PCDLBCL- NOS non- germinal center B- cell.
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the histopathologist’s standpoint, the major challenge is 
the proper classification of PCBCL displaying a diffuse 
pattern and a predominant large cell histology.
We defined PCDLBCL- NOS as a subset of cases exhibit-
ing diffuse large B- cell histology, not fitting into PCFCCL 
diffuse type subgroup nor in PCDLBCL- LT both in cytol-
ogy and in phenotype. PCDLBCL- NOS predominantly 
consisted of centroblasts, often intermingled with a brisk 
infiltrate of small lymphocytes, which are usually incon-
spicuous in PCDLBCL- LT. However, PCDLBCL- NOS dif-
fered from PCFCCL because large centrocytoid cells 
represented only a limited fraction (<10%) of the infiltrate, 
whereas no dendritic meshwork was detectable other than 
minimal remnants (in a minority of cases). Phenotypically, 
they variably expressed MYC and BCL2 that were intensely 
coexpressed in PCDLBCL- LT. PCDLBCL- NOS partially 
overlapped with the subset of PCDLBCL- other as described 
in the 2005 WHO/EORTC classification [7, 8] and by 
Kodama et al. [14], where they are reported to have his-
tologic features in between PCFCCL and PCDLBCL- LT, 
showing predominance of round cells and variable BCL2 
expression.
We aimed to clarify whether PCDLBCL- NOS represents 
a distinct clinicopathologic subset or simply a morpho-
phenotypic variant of PCFCCL and/or PCDLBCL- LT by 
analyzing their outcome. Comparison of PCDLBCL- NOS 
as a whole with PCFCCL resulted in a difference in OS, 
though below the threshold of significance. Separation of 
PCDLBCL- NOS upon histogenetic profile documented a 
worse prognosis for the non- GC subgroup, whereas cases 
with a GC profile were more similar to PCFCCL. Since 
PCDLBCL- NOS with a GC profile cannot be distinguished 
from the more aggressive PCDLBCL- NOS with a non- GC 
profile on the sole morphological ground, we think that 
a more accurate prognostic stratification of this category 
should rely on the immunophenotypic and/or molecular 
characterization. As well, cases of PCDLBCL- NOS with a 
non- GC profile would be classified by some pathologists 
as PCFCCL [15] with high content of blast cells, but they 
are different in terms of both clinical course and outcome 
(shorter survival) as compared to PCFCCL. Although the 
small number of cases of PCDLBCL- NOS with a non- GC 
phenotype did not allow us to reach a statistical signifi-
cance when comparing their outcome to PCDLBCL- LT, 
a trend toward a less aggressive course was observed. 
Notably, PCDLBCL- NOS- non- GC clearly differs from 
PCDLBCL- LT in terms of presentation site, cytologic fea-
tures (centroblasts with an intermixed reactive infiltrate), 
and phenotype (rare MYC/BCL2 coexpression).
Since the description of PCDLBCL- LT by Vermeer et al. 
[16], the concept of PCDLBCL has been tightly connected 
to a specific anatomic location on the lower limbs, as 
well as the “leg” involvement denoted a poor prognostic P
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indicator. Further series reported an analogous behavior 
for PCDLBCL- LT arising at different sites [3]. Our study 
highlights that the prognostic role of the leg location is 
retained on the whole series but not in PCDLBCL- LT 
alone, which in turn arises more frequently in the lower 
extremities. This finding suggests that histopathology and 
other biologic factors rather than “leg” location only might 
be predictive of a potential aggressive behavior.
First- line treatment was mainly radiotherapy in PCFCCL 
(49%) and chemotherapy (±local radiotherapy) in both 
PCDLBCL- LT (60%) and PCDLBCL- NOS (55%). 
However, follow- up data of PCDLBCL- NOS were more 
similar to PCFCCL and complete response and relapse 
rate and number of patients alive free of disease consist-
ently differed from PCDLBCL- LT (Table 2). With the 
limitations of a retrospective data collection, these obser-
vations suggest the opportunity of a radiotherapy- privileged 
first- line treatment for PCDLBCL- NOS, particularly in 
cases with a GC profile.
PCFCCL and PCDLBCL- LT harbor different molecular 
profiles [4–6, 17, 18]; however, only limited data are avail-
able on the above- mentioned subset with features in between 
PCFCCL and PCDLBCL- LT [19]. We applied Hans algo-
rithm, as a surrogate of gene expression profiling (GEP) 
to define the histogenesis, and DHS to test the prognostic 
impact of two immunohistochemical algorithms validated 
in the diagnostic workup of systemic DLBCL [12, 13]. 
We are well aware that immunohistochemical algorithms 
remain an imperfect substitution of GEP, partly due to 
their inherent oversimplification; nonetheless they provide 
a practical way of designating subtype and may be suf-
ficient for the purpose of achieving population enrichment 
on clinical trials, although being less reliable for individual 
patient management [20]. However, our results seem to 
enhance the concept of cell- of- origin and its prognostic 
relevance also in the setting of PCBCL, since we distin-
guished PCDLBCL- NOS with a non- GC phenotype as 
having an intermediate behavior between classic PCFCCL 
and PCDLBCL- LT. As to DHS, though basing on a limited 
number of cases, BCL2/MYC coexpression proved helpful 
to identify cases with a more aggressive course among the 
whole group of PCDLBCLs, in a way independent from 
the histology. The latter observation was confirmed also 
for the sole BCL2 positivity. However, the definition of 
the genetic landscape of PCDLBCL- NOS in comparison 
with PCDLBCL- LT and PCFCCL could be a matter of 
future interest.
Currently no widely accepted prognostic indicators exist 
for PCFCCL. Similarly to previous reports, our series of 
PCFCCL showed an excellent prognosis with a 5- year 
disease- specific survival over 95% and only two patients 
dead of progression to systemic lymphoma. In our series, 
leg presentation and presence of t(14;18)(q32;q21) adversely 
affected prognosis. Whereas the former has been already 
associated with a more aggressive course [3], the prog-
nostic role of t(14:18) is still debated.
t(14;18)(q32;q21) involves BCL2 and IGH and rep-
resents the cytogenetic hallmark of nodal follicular 
lymphoma, whereas its detection in PCFCCL requires 
to exclude a secondary localization [21]. BCL2 trans-
location has been variably detected in PCFCCL both 
in studies using polymerase chain reaction (PCR)- based 
methods (0–34%) and FISH analysis (0–41%) (Table 5) 
[21–33]. Possible explanations for this wide range 
include geographic distribution, the limited number 
and heterogeneity of at least some of the reported 
series, and variation in the diagnostic criteria in dif-
ferent studies, probably including cases of skin 
Table 5. Comparison of BCL2 evaluation in PCFCCL among series.
Evaluation of BCL2 IHC PCR FISH
Cerroni et al., 2000 [22] 0/15 0/15 NA
Franco et al., 2001 [21] 11/18 (61%) 0/18 NA
Bergman et al., 2001 [23] 4/19 (21%) 2/15 (13%) NA
Aguilera et al., 2001 [24] 11/18 (61%) 3/17 (18%) NA
Child et al., 2001 [25] 0/25 0/25 NA
Lawnicki et al., 2002 [26] 8/20 (40%) 4/20 (20%) NA
Goodlad et al. 2002 [27] 3/16 (81%) 0/16 NA
Mirza et al., 2002 [28] 13/32 (41%) 11/32 (34%) NA
Vergier et al., 2004 [29] 17/30 (57%) 9/30 (30%) 0/17
Kim et al., 2005 [30] 17/30 (57%) NA 4/13 (31%)
Streubel et al., 2006 [31] 10/27 (37%) 0/17 11/27 (41%)
Abdul- Wahab et al., 2014 [32] 6/57 (11%) NA 4/49 (8%)
Pharm Ledard et al., 2015 [33] 25/47 (53%) NA 4/47 (8.5%)
Present series 29/96 (30%) NA 15/75 (20%)
BCL2, B- cell lymphoma; PCFCCL, primary cutaneous follicular center cell lymphoma; IHC, immunohistochemistry; PCR, polymerase chain reaction; 
FISH, fluorescence in situ hybridization; NA, not assessed.
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involvement in the course of systemic follicular lym-
phoma. The clinical relevance of BCL2 rearrangement 
in PCFCCL is controversial. Abdul- Wahab et al. [32] 
reported that chromosomal anomalies, including 
t(14;18), do not portend a poor prognosis, as BCL2- 
translocated patients do not differ in terms of clinical 
outcome and invariably respond to radiotherapy. On 
the contrary, Pharm Ledard et al. [33] reported that 
BCL2 rearrangement correlates to a higher risk of 
extracutaneous spread.
To the best of our knowledge, the present series is 
the largest ever tested for BCL2 rearrangement, encom-
passing the entire histologic spectrum of PCFCCL 
according to the WHO classification. FISH was preferred, 
due to its higher sensitivity for detection of IGH/BCL2 
rearrangement than PCR [31]. We documented t(14;18)
(q32;q21) in 15/75 (18%) patients, of which seven 
patients experienced cutaneous relapses and one patient 
died after systemic progression. Discordance between 
the presence of BCL2 translocation and protein expres-
sion is a well- reported occurrence in a limited fraction 
of systemic FL, which may lie with mutational events 
at BCL2 locus [34]. We tested our cases using BCL2 
clone 124, and a significant correlation was found 
between protein expression and t(14;18), since it occurred 
in 48% BCL2- positive cases but only in 8% BCL2- 
negative cases (P < 0.001). While the presence of t(14;18) 
was associated with decreased OS, BCL2 expression did 
not seem to affect prognosis: as a consequence, FISH 
analysis could be included in the PCFCCL work- up, 
to identify patients requiring closer monitoring.
Our findings indicate that PCLBCL includes different 
subsets, among which the so- called leg type probably rep-
resents an aggressive clinical variant; a further group may 
exist, exhibiting clinicopathologic features intermediate 
between PCFCCL and PCDLBCL- LT. Careful combination 
of morphological and immunophenotypic criteria with 
adequate clinical information is crucial to identify such 
cases.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. The typical picture of PCFCCL displays a 
nodular (A, hematoxylin–eosin 20×) to diffuse proliferation 
composed of small- to medium- sized centroblasts (B, hema-
toxylin–eosin 400×), with a variable proportion of centroblast 
or with a spindle cell morphology (C, hematoxylin–eosin 
200×). BCL2 is usually negative (D, SABC method, 400×) 
and CD10 is positive (E, SABC method, 200×), whereas 
a residual, CD23+ positive dendritic meshwork is typically 
present (F, SABC method, 200×).
Figure S2. A representative picture of the presence of 
t(14;18) is depicted (A, IGH/BCL2 Dual Color, Dual Fusion 
Translocation Probe, 1000×). EBV status was invariably 
negative (B, EBER- ISH, 400×); slides taken from non-
keratinizing undifferentiated nasopharyngeal carcinoma 
were used as positive control (B, inset).
